Tuesday 5 November 2024

The Pharma Letter Podcast — Episode 19 — US midterms and beyond: outlook for pharma

Pharmaceutical
Simon Wentworth
28 November 2022
us-midterms-and-beyond-1

More on this story...

Pharmaceutical
The Pharma Letter Podcast — Episode 17 — Inflation Reduction Act: quick take
17 August 2022
Pharmaceutical
Biden-Harris Administration moves on affordable and accessible healthcare
27 October 2022
Pharmaceutical
Biden names Renee Wegrzyn as first head of ARPA-H
13 September 2022


More ones to watch >


Today's issue

PharmaMar gets $10 million milestone from Janssen for Yondelis
Pharmaceutical
PharmaMar gets $10 million milestone from Janssen for Yondelis
5 November 2024
Pharmaceutical
Photocure’s Hexvix wins Chinese approval
5 November 2024
Pharmaceutical
Vertex ups guidance again as results exceed estimates
5 November 2024
Biotechnology
Transgene and ProBioGen join forces on cancer vaccines
5 November 2024
Biotechnology
Nxera Pharma and Antiverse partner on GPCRs
5 November 2024
Pharmaceutical
Positive results for Neurocrine’s Ingrezza in tardive dyskinesia
5 November 2024
Pharmaceutical
Boehringer mental health tie-up worth up to $126.5 million to Broad Institute
4 November 2024

Company Spotlight

A Denmark-headquartered company that currently has a pipeline of three independent endocrinology rare disease product candidates in clinical development and is advancing oncology as its second therapeutic area of focus.




More Features in Pharmaceutical

PharmaMar gets $10 million milestone from Janssen for Yondelis
5 November 2024
Photocure’s Hexvix wins Chinese approval
5 November 2024
Vertex ups guidance again as results exceed estimates
5 November 2024
Positive results for Neurocrine’s Ingrezza in tardive dyskinesia
5 November 2024


Copyright © The Pharma Letter 2024   |   Headless Content Management with Blaze